Effectiveness of MESNA on the success of cholesteatoma surgery.
OBJECTIVE
It is important that chronic otitis media with cholesteatoma be treated successfully in patients to protect them from having repeated surgeries with related surgical co-morbidities and hearing loss.


OBJECTIVE
To evaluate the effectiveness of MESNA usage on the residual cholesteatoma rates of the patients who underwent surgery due to chronic otitis media with cholesteatoma.


METHODS
Retrospective single-institution study of a prospectively collected database.


METHODS
Tertiary University Hospital.


METHODS
Nine hundred and thirty-four patients underwent surgery due to chronic otitis media between September 2000 and March 2012 by the same surgeon. One hundred and forty-one cases out of 934 patients were selected who had cholesteatoma for the study. These randomly selected 141 cases were divided into two groups as follows: I. Forty-six cases were applied MESNA (Sodium 2-mercaptoethanesulfonate) intraoperatively, and II. Ninety-five cases were not applied MESNA intraoperatively. The cases that were followed-up at least one year were included in this study.


METHODS
MESNA (Ureomitexan, MESNA, Baxter oncology, Germany) was diluted with saline (20% MESNA and 80% saline) that was applied, and then a waiting period of approximately 5 min followed to start to dissect cholesteatoma matrix.


METHODS
Residual cholesteatoma rates between intraoperative MESNA, a disulfide bond breaking chemical agent, applied and MESNA non-applied cases in the postoperative follow-up period were compared for the success of the surgery.


RESULTS
MESNA was used in 46 patients out of 141 cases intraoperatively. Twenty-four of these patients underwent CWD (canal wall down), and twenty-two patients underwent CWU (canal wall up) mastoidectomy. For the other 95 subjects, 56 patients with CWD and 39 with CWU mastoidectomy, MESNA was not applied. Residual cholesteatoma rates were found to be significantly higher in MESNA non-applied group than MESNA applied group (p<0.05). Residual cholesteatoma rates between CWD and CWU mastoidectomy procedures were not statistically significant (p>0.05).


CONCLUSIONS
MESNA application that breaks disulfide bonds in the structure of the matrix in cholesteatoma surgery may assist the elimination of the disease, and increase surgical success by facilitating the elevation of the epithelium. Thereby, it causes a decrease in the possibility of remaining residual epithelium after surgery, which decreases the need for second-look surgery.


BACKGROUND
The retrospective research protocol was approved by the Inonu University Clinical Research Ethics Committee.


BACKGROUND
………
Istanbul Medeniyet University Medical Faculty, Department of Otorhinolaryngology, Istanbul. Electronic address: mtkalcioglu@hotmail.com.
M Tayyar
MT
Kalcioglu
Inonu University Medical Faculty, Department of Otorhinolaryngology, Malatya. Electronic address: turancicek@gmail.com.
Mehmet T
MT
Cicek
Inonu University Medical Faculty, Department of Otorhinolaryngology, Malatya. Electronic address: tbayindir@inonu.edu.tr.
Tuba
T
Bayindir
Goztepe Training and Research Hospital, Istanbul, Turkey. Electronic address: osmanilkay73@yahoo.com.
Osman Ilkay
OI
Ozdamar
D000328:Adult; D002781:Cholesteatoma / Q000601:surgery*; D002908:Chronic Disease; D005260:Female; D006801:Humans; D008297:Male; D015080:Mesna / Q000008:administration & dosage / Q000627:therapeutic use*; D010033:Otitis Media / Q000150:complications / Q000601:surgery; D011300:Preoperative Care; D020011:Protective Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D012189:Retrospective Studies; D016896:Treatment Outcome
D020011:Protective Agents; D015080:Mesna